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ABSTRACT Definitive radiochemotherapy is the standard treatment for many patients with locally
advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades.
Several treatment regimens have been shown effective and safe. This review summarises the results of
significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens
and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable
to improve outcome and minimise radiation-induced toxicity. An insight into the rationale of radiotherapy
planning for stage III NSCLC is also provided.
@ERSpublications
Concomitant radiochemotherapy is an established standard treatment for locally advanced nonsmall
cell lung cancer http://ow.ly/TTkkc
Introduction
Radio(chemo)therapy has been an important part of lung cancer treatment for several decades and its
recent advances have led to significant improvements in treatment outcomes. The current review will focus
on the application of radiotherapy for locally advanced nonsmall cell lung cancer (NSCLC).
Lung cancer is one of the most common causes of cancer death, with many patients diagnosed in a locally
advanced stage. Although the treatment outcome has improved over the last decades, it remains poor [1].
Locally advanced lung cancer is a heterogeneous group and the definition often overlaps with stage III
lung cancer. Typically patients with stage I/II lung cancer would be primarily considered for curatively
intended surgery or stereotactic body radiotherapy in case of inoperability. Stage IV patients would
typically receive palliative treatment [2], often involving systemic agents while nowadays multimodal
concepts are being tested in oligo-metastatic cases.
Staging
An essential part of lung cancer staging is proper mediastinal lymph node staging, which may be achieved
by fine needle aspiration (e.g. endobronchial ultrasound guided biopsies, transoesophageal biopsies),
mediastinoscopy, 18-fluorodeoxyglucose positron emission tomography or a combination of these. When
mediastinal lymph nodes are limited to the ipsilateral mediastinum, it is considered N2 (stage IIIA: T1–3
N2 or T4 N1) disease, while contralateral involvement denotes N3 disease (stage IIIB: T1–3 N3 or T4 N2).
While stage IIIB N3 is generally not amenable to surgery [3], certain subsets of stage IIIA N2 disease are
approachable with surgery. To help differentiate, the American College of Chest Physicians has published
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a sub-classification of N2 disease [4]. Typically bulky and/or multi-level N2 disease is associated with a
high rate of micro-metastatic spread and extensive mediastinal involvement. In this setting as well as in
stage IIIB, definitive radio-chemotherapy is the standard treatment.
Radiotherapy alone
Radiotherapy delivers ionising radiation, which in turn causes physical and chemical interactions leading
to DNA and other tumour damage. Repetitive exposure to appropriate doses of radiation causes increased
damage to tumour cells when compared to healthy tissue. This is the basis of conventionally fractionated
radiotherapy, where typically a dose of 2 Gy is delivered five times per week.
Currently a daily fraction of 1.8–2 Gy is considered standard for lung cancer. Alternative dose-fractionation
schedules have been investigated, especially for patients who are not suitable for concurrent chemotherapy.
Several clinical trials in the last two decades show a survival benefit of hyperfractionated radiotherapy
(twice or three times a day with doses <1.8 Gy) over conventional fractionation [5, 6]. However one of the
latest studies, the randomised phase III CHARTWEL (Continuous Hyperfractionated Accelerated
Radiotherapy Weekend-less) trial (ARO 97-1) [7], showed no difference in outcome between 60 Gy in 40
fractions over 2.5 weeks (CHARTWEL) or 66 Gy in 33 fractions over 6.5 weeks. However, in comparison to
previous trials the rate of squamous histology in the CHARTWEL trial was lower, which is the subgroup
that seems to benefit most from accelerated RT [8].
For patients with early stage NSCLC who are medically inoperable a good option is hypofractionated/
stereotactic radiation therapy [9–12]. There is a clear benefit for a biological effective dose >100 Gy in NSCLC
[13–15]. What about high-dose/fraction treatments for stage III NSCLC? There are some studies with
dose-accelerated schedules, using doses between 45 and 60 Gy in 3–15 fractions with promising local control
rates and acceptable toxicity [16–18]. While the results of ongoing randomised trials on hypofractionated
radiotherapy have to be awaited, a recent meta-analysis has already confirmed the role of accelerated
hyperfractionation resulting in an absolute benefit of 2.5% in overall survival (8.3–10.8%) at 5 years [19].
Radiochemotherapy
Radiotherapy alone has demonstrated reasonable response rates for locally advanced NSCLC, however the
outcomes were very poor [20, 21]. The introduction of sequential radiochemotherapy has led to an
increase of overall survival from approximately 5% to 10% at 5 years with the addition of chemotherapy
[22–24]. With the implementation of concurrent radiochemotherapy this rate rose to 15% with an
absolute survival benefit of 4.5% at 5 years [25].
Although concurrent radiochemotherapy is associated with improved overall survival when compared with
sequential treatment [1, 26–30] (table 1), the latter is associated with lower toxicity (less oesophagitis/
pneumonitis). Thus, concomitant treatment is the preferred strategy for fit patients but sequential
chemo-radiotherapy may be applied in selected cases (e.g. the elderly or those with poor performance
status) for whom a concomitant radiochemotherapy is not deemed feasible.
Several regimens have been established in combination with radiotherapy. Doublet chemotherapy results in
better progression-free survival rates than concomitant single-agent chemotherapy [25]. Platinum-based
chemotherapy regimens are a standard of treatment [27]. These include: cisplatin (Cis)/etoposide (Eto),
Cis/vinorelbine, Cis/vindesine, Cis/mitomycine/vindesine, Cis/docetaxel, Cis/gemcitabine, carboplatin
(Carbo)/paclitaxel, Carbo/irinotecan, Carbo/Eto [1, 28–40]. The 5-year overall survival for the mentioned
regimens is around 15–20%. Patient comorbidities may help guide the choice of agent. While overall
survival seems to be similar with these, less haematological toxicity but a higher risk of radiation
pneumonitis was observed with Carbo/paclitaxel when compared to Cis/Eto [41]. Pemetrexed (Pem)/Cis
seems to have a survival benefit for patients with metastatic non-squamous NSCLC [42]; however, no clear
advantages are reported in locally advanced disease. In the PROCLAIM study presented at the American
Society of Clinical Oncology Annual Meeting in 2015, concurrent Pem+Cis arm did not improve OS
versus Cis/Eto, but did have a better safety profile [43].
Effective novel chemotherapy agents or targeted therapies, such as cetuximab, bevacizumab, gefitinib or
anti-PD-1 inhibitors have so far led to rather disappointing results in combination with radiotherapy and
may even bear the risk of unexpected toxicities like fistula, oesophagitis and bleeding [44–47]. So far, there
is not enough evidence to support their routine use in radiochemotherapy protocols.
Planning
After obtaining imaging a planning computed tomography (CT), the typical procedure is to define the
gross tumour volume (GTV), which represents the macroscopic tumour. Based on several investigations
[48, 49], including histological evaluation of microscopic extensions the clinical target volume (CTV) is
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typically formed by adding 6–10 mm to the GTV in all directions (except where natural barriers would be
expected, e.g. bone, pleura). Due to positioning and calculation inaccuracies, a further margin is added to
create the planning target volume.
While imaging has generally improved and staging has become more precise, technological advancements
have also helped in dealing with an obvious problem in radiotherapy for lung cancer: tumour movement.
This has led the International Commission on Radiation Units to implement a new volume, internal target
volume (ITV), which is used to account for tumour motion, primarily through breathing. Modern
radiation oncology dedicated CT-scanners are capable of four-dimensional CTs, this means that imaging is
acquired over different phases of the breathing cycle and the collected images are binned to create a
“breathing” CT, which serves as a basis for the ITV. An alternative approach is to irradiate the CTV in a
specific breathing phase (e.g. only inhalation or exhalation) using phased-gating or tracking, where small
target volumes are irradiated and therefore an ITV is omitted.
Initially, mediastinal lymph nodes were irradiated electively, meaning they were irradiated beyond the
involved lymph nodes. One of the first trials investigating this was performed by YUAN et al. [50]. This
trial compared 74 Gy to only involved nodes (involved field irradiation) and compared it with 60 Gy to
include elective nodal stations (elective nodal irradiation). Involved field irradiation was associated with










BRADLEY [1] 2015 Phase III Carboplatin/paclitaxel (con)
+/- cetuximab (cons)
60 Gy 2 Gy 57.6% (2-year OS)
Carboplatin/paclitaxel (con)
+/- cetuximab (cons)
74 Gy 2 Gy 44.6% (2-year OS)
OH [31] 2013 Phase III Cisplatin/paclitaxel (con/cons) 60–66 Gy 2–2.4 Gy Median OS 27.3 months
Cisplatin/docetaxel (con/cons) 60–66 Gy 2–2.4 Gy Median OS 27.6 months
Cisplatin/gemzitabine (con/cons) 60–66 Gy 2–2.4 Gy Median OS 16.5 months
CURRAN [30] 2011 Phase III Cisplatin/vinblastin (con) 60 Gy 2 Gy 16.0%
Cisplatin/vinblastin (seq) 60 Gy 2 Gy 10.0%
Cisplatin/etoposide (con) 69.6 Gy 1,2 Gy twice
a day
13.0%
SEGAWA [32] 2010 Phase III MVP (con) 60 Gy 2 Gy 16.6%
Docetaxel/cisplatin (con) 60 Gy 2 Gy 17.5%
YAMAMOTO [33] 2010 Phase III MVP (con) 60 Gy 2 Gy 17.5%
Carboplatin/irinotecan (con) 60 Gy 2 Gy 17.5%
Carboplatin/paclitaxel (con) 60 Gy 2 Gy 19.5%
HANNA [29] 2008 Phase III Cisplatin/etoposide (con) 59.4 Gy 1.8 Gy 26.1% (3-year OS)
Cisplatin/etoposide (con) + docetaxel
(cons)
59.4 Gy 1.8 Gy 27.1% (3-year OS)
GOUDA [28] 2006 Randomised Paclitaxel/carboplatin (con) 60 Gy 2 Gy 45% (2-year OS)
Paclitaxel/carboplatin (ind/con) 60 Gy 2 Gy 40% (2-year OS)
No chemotherapy 60 Gy 2 Gy 10% (2-year OS)
FOURNEL [34] 2005 Phase III Cisplatin/etoposide (con) 66 Gy 2 Gy 21% (4-year OS)
Cisplatin/vinorelbine (seq) 66 Gy 2 Gy 14% (4-year OS)
ZATLOUKAL [35] 2004 Randomised Cisplatin/vinorelbine (con) 60 Gy 2 Gy 18.6% (3-year OS)
Cisplatin/vinorelbine (seq) 60 Gy 2 Gy 9.5% (3-year OS)
ALBAIN [36] 2002 Phase II Cisplatin/etoposide (con) 60 Gy 2 Gy 15.0%
FURUSE [37] 1999 Phase III MVP (con) 56 Gy 2 Gy 15.8%
MVP (seq) 56 Gy 2 Gy 9.0%
LEE [38] 1996 Phase II Cisplatin/etoposide (con) 69.6 Gy 1,2 Gy twice
a day
35% (2-year OS)
JEREMIC [39] 1996 Randomised Carboplatin/etoposide (con) 69.6 Gy 1,2 Gy twice
a day
23% (4-year OS)
No chemotherapy 69.6 Gy 1,2 Gy twice
a day
9% (4-year OS)
DILLMAN [40] 1996 Phase III Cisplatine/vinblastine (con) 60 Gy 2 Gy 17%
No chemotherapy 60 Gy 2 Gy 7%
OS: overall survival; Con: concurrent; cons: consolidation; seq: sequential; MVP: mitomycin, vindesine, and cisplatin; ind: induction.
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lower rates of radiation-induced pneumonitis and improved local control when compared with
prophylactic lymph node irradiation. Several other trials have confirmed this approach also demonstrating
the rate of recurrence in elective nodal regions at <5% [51–53]. However, nearly all evidence on this topic
derives from the three-dimensional conformal radiotherapy era with a relevant proportion of unaffected
mediastinum being treated by incidental therapeutic doses. Except the single-centre prospective evidence
from YUAN et al. [50], all data derive from retrospective series or secondary analyses. Despite this, the
concept of involved node radiotherapy has become standard for locally advanced NSCLC radiotherapy to
date. Recently, new data on a higher rate of out-of-field recurrences after more conformal planning and
intensity-modulated radiotherapy [54] have arisen, so that further analyses and the result of running
prospective trials may again change our perception here.
Dose escalation has been discussed and investigated for years. While several phase I–II trials have
demonstrated improvement of local control, hard evidence for dose escalation beyond 60 Gy was lacking. The
Radiation Therapy Oncology Group (RTOG) 0617 trial tested a dose escalation of 74 Gy versus 60 Gy.
Surprising to many, the higher-dose arm was not associated with improved survival at 1 year but rather
showed a contrary trend and the dose escalation arms were closed based on interim analysis [55]. Despite
several doubts [56] about the causes involved in this result, the current standard of care is a radiation dose of
60–66 Gy and further dose escalation is still regarded as being experimental. This is also supported by the
recent guidelines of the American Society for Therapeutic Radiation Oncology [57]. In many aspects, they are
similar to the recommendations of the European Organisation for Research and Treatment of Cancer [58].
Thanks to modern treatment planning systems, it is possible to calculate the healthy tissue (organs at risk)
doses in a respective radiotherapy plan. For decades, a consensus-based paper by EMAMI et al. [59] served
as a pivot to predict tolerability of treatment. Due to an evidence-based pooled analysis of RTOG, the
QUANTEC [60] project produced data that is currently used to predict the side effects of radiotherapy
and the tolerability of evaluated treatment plans. Toxicities of radiotherapy typically include the organs
that are irradiated due to their adjacency to the tumour. These include primarily organs of the thorax,
specifically: the spinal cord [61], the lungs [62], the heart [63] and the oesophagus [64]. The typical
constraints that are usually aimed for are: volume of organ receiving at least 20 Gy less than 30–35% and a
mean lung dose of under 20–23 Gy. The volumes and doses in most analyses have considered the total
lung volume, however individual (ipsi- and contralateral) lung doses have been also demonstrated to be
predictive of radiation pneumonitis [5, 65]. When the appropriate criteria are taken into account the risk
of side effects can be reduced and treatments become better tolerated.
Conclusion
Radiochemotherapy has an established role in the treatment of stage III lung cancer. Modern radiotherapy
techniques may contribute to reducing toxicities. Concurrent chemotherapy is typically a platin-based
doublet therapy. Whenever possible, concurrent radiochemotherapy is preferred, whereas for individual
patients a sequential approach might be feasible.
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